Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and outlined its strategic priorities for 2026. The company continues to advance its physics+AI computational platform, reinforcing its position as a global leader in computational molecular discovery. In 2025, Schrödinger observed the growing impact of integrating physics-based modeling with artificial intelligence to address persistent challenges in drug discovery, particularly data scarcity. This hybrid approach has enabled more accurate predictions and faster identification of novel, high-potential molecules. The company’s platform has been instrumental in helping partners de-risk early-stage research and accelerate the path from target identification to clinical candidates. Schrödinger highlighted key advancements in its technology, including improvements in protein-ligand binding prediction, de novo molecule design, and the ability to model complex biological systems with greater precision. These capabilities are being applied across a range of therapeutic areas, including oncology, neurology, and rare diseases. Looking ahead to 2026, the company is focused on three core strategic priorities. First, it will deepen the integration of AI with first-principles physics to further enhance model accuracy and generalizability. Second, Schrödinger plans to expand its platform’s accessibility and usability, making its tools more intuitive for researchers across biopharma, academic institutions, and emerging AI-driven drug discovery startups. Third, the company will continue to strengthen its partnerships with major pharmaceutical companies and biotech innovators, supporting co-development of next-generation therapeutics. Schrödinger also emphasized its commitment to building a robust ecosystem around its platform, including expanded data curation, enhanced cloud infrastructure, and new tools for real-time collaboration. The company remains dedicated to driving innovation in computational science, with the goal of transforming how molecules are discovered and developed. As the field of AI-driven drug discovery evolves, Schrödinger is positioning itself at the forefront, combining rigorous scientific principles with cutting-edge technology to deliver real-world impact in the fight against disease.